Cochrane · systematic review · CD009733
Antifibrinolytics (lysine analogues) for the prevention of bleeding in people with haematological disorders
Estcourt, LJ, Desborough, M, Brunskill, SJ, et al. · Cochrane Database of Systematic Reviews · 2016 · Cochrane Library
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
7
current version
GRADE rated
3
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 4 · 57.1%Very low 3 · 42.9%Low 0 · 0%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Current version onlyAntifibrinolytics (lysine analogues) compared to placebo to prevent bleeding in people with haematological disorders
Population: people with haematological disorders
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Number of participants with any bleeding Antifibrinolytics (lysine analogues) vs placebo | no estimate extracted | 1 study · 56 participants | Very low Downgraded: risk of bias, imprecision |
Number of participants with thromboembolism Antifibrinolytics (lysine analogues) vs placebo | no estimate extracted | 2 studies · 68 participants | Very low Downgraded: risk of bias, imprecision |
Mortality (all‐cause) ‐ not reported Antifibrinolytics (lysine analogues) vs placebo | no estimate extracted | 0 studies · 0 participants | Ungraded |
Number of platelet transfusions per participant ‐ not reported Antifibrinolytics (lysine analogues) vs placebo | no estimate extracted | 0 studies · 0 participants | Ungraded |
Adverse events of transfusions ‐ not reported Antifibrinolytics (lysine analogues) vs placebo | no estimate extracted | 0 studies · 0 participants | Ungraded |
Adverse events of antifibrinolytic agents Antifibrinolytics (lysine analogues) vs placebo | no estimate extracted | 2 studies · 74 participants | Very low Downgraded: risk of bias, imprecision |
Quality of life ‐ not reported Antifibrinolytics (lysine analogues) vs placebo | no estimate extracted | 0 studies · 0 participants | Ungraded |
Antifibrinolytics (lysine analogues) compared to placebo to prevent bleeding in patients with haematological disorders
Population: patients with haematological disorders
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Number of patients with any bleeding Antifibrinolytics (lysine analogues) vs placebo | no estimate extracted | 3 studies · 86 participants | Very low Downgraded: risk of bias, imprecision |
Number of patients with thromboembolism Antifibrinolytics (lysine analogues) vs placebo | no estimate extracted | 2 studies · 68 participants | Very low Downgraded: risk of bias, imprecision |
Mortality (all‐cause) Antifibrinolytics (lysine analogues) vs placebo | no estimate extracted | 0 studies · 0 participants | Ungraded |
Number of platelet transfusions per patient Antifibrinolytics (lysine analogues) vs placebo | no estimate extracted | 0 studies · 0 participants | Ungraded |
Adverse events of transfusions Antifibrinolytics (lysine analogues) vs placebo | no estimate extracted | 0 studies · 0 participants | Ungraded |
Adverse events of antifibrinolytic agents Antifibrinolytics (lysine analogues) vs placebo | no estimate extracted | 2 studies · 74 participants | Very low Downgraded: risk of bias, imprecision |